580 related articles for article (PubMed ID: 19135705)
1. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
[TBL] [Abstract][Full Text] [Related]
2. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
3. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
4. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
5. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
7. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
8. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
9. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
Hochholzer W; Trenk D; Frundi D; Neumann FJ
Thromb Res; 2007; 119(3):285-91. PubMed ID: 16603231
[TBL] [Abstract][Full Text] [Related]
10. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Gilard M; Arnaud B; Cornily JC; Le Gal G; Lacut K; Le Calvez G; Mansourati J; Mottier D; Abgrall JF; Boschat J
J Am Coll Cardiol; 2008 Jan; 51(3):256-60. PubMed ID: 18206732
[TBL] [Abstract][Full Text] [Related]
11. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Siller-Matula JM; Lang I; Christ G; Jilma B
J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS
Platelets; 2010; 21(3):183-90. PubMed ID: 20201634
[TBL] [Abstract][Full Text] [Related]
13. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
14. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
Bonello L; Camoin-Jau L; Arques S; Boyer C; Panagides D; Wittenberg O; Simeoni MC; Barragan P; Dignat-George F; Paganelli F
J Am Coll Cardiol; 2008 Apr; 51(14):1404-11. PubMed ID: 18387444
[TBL] [Abstract][Full Text] [Related]
15. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy.
Arméro S; Camoin Jau L; Omar Aït Mokhtar O; Mancini J; Burignat-Bonello C; Tahirou I; Arques S; Dignat-George F; Paganelli F; Bonello L
Platelets; 2010; 21(7):503-7. PubMed ID: 20670107
[TBL] [Abstract][Full Text] [Related]
16. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
[TBL] [Abstract][Full Text] [Related]
17. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
[TBL] [Abstract][Full Text] [Related]
19. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
20. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
Gajos G; Rostoff P; Undas A; Piwowarska W
J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
